Natco launches cut-price copies of AstraZeneca's patented anti-diabetes drug

The launch gives Natco an entry in the rapidly growing SGLT-2 segment
that has mostly been dominated by global drug makers. However, for
roughly a year, the segment has seen the entry of Indian drug maker
Glenmark, which launched its versions of remogliflozin at a
significantly lower price than MNC brands.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-launches-cut-price-copies-of-astrazenecas-patented-anti-diabetes-drug/articleshow/75022602.cms